AdaptHealth Corp. (AHCO) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AdaptHealth said Q1 was 'extraordinary' operationally, with all four business segments growing organically for the first time since the company reorganized into those segments. Core sleep and respiratory businesses grew 3% to 4% year over year, while management framed the EBITDA shortfall as driven by temporary cost items rather than a deterioration in underlying demand. The discussion was primarily an update on first-quarter performance and the expected timing of cost recovery into Q2.

Analysis

The key signal is not the modest Q1 miss; it is that all four end markets are now inflecting at once, which suggests the business is moving from a cost-repair story to a volume/mix recovery story. That matters because in DME, operating leverage is asymmetric: once fixed service and logistics infrastructure is covered, even low-single-digit organic growth can translate into a much larger EBITDA delta over the next 2-3 quarters. If the core sleep/respiratory franchise is really holding 3%-4% organic growth, the market may be underestimating how quickly margin pressure from one-off items can wash out.

The second-order effect is competitive. A broad-based recovery in AHCO’s categories likely tightens placement capacity and inventory allocation for smaller regional providers that rely on the same payer and supplier relationships. If AdaptHealth is successfully normalizing service levels while preserving growth, it can force less-scaled peers to compete on price or surrender referral flow, especially in sleep where patient acquisition and replenishment economics are sticky over months rather than days.

The contrarian angle is that consensus likely treats the Q1 EBITDA shortfall as evidence of structural execution slippage, when the bigger risk may be the opposite: the market is missing the upside from a multi-quarter normalization in operating expenses and working capital. The stock should re-rate if management shows that the margin headwinds were mostly timing-related and Q2 exits with cleaner cost run-rate. The main risk is if the growth print is masking payer mix deterioration or higher service intensity, which would cap margin recovery and make the inflection look temporary rather than durable.

Key Decisions for Investors

• Go long AHCO for a 2-3 month tactical trade into the next quarterly print; risk/reward is attractive if management confirms Q1 costs were transitory and EBITDA margin expands sequentially, with downside limited if the market has already priced the miss.
• Use AHCO as a long vs. short pair against a lower-quality DME/provider basket or any weaker outsourced healthcare services name with similar reimbursement exposure; the spread should widen if capital begins favoring scaled operators with better operating leverage.
• Buy AHCO call spreads 1-2 quarters out to express a recovery in EBITDA without taking full delta risk; structure for a 2:1 or better payoff if sequential margin recovery becomes visible.
• If AHCO rallies sharply on a clean Q2 guide, trim into strength rather than chase; the market may front-run normalization before the actual numbers prove it.